Alphatec CEO Miles Patrick Purchases 115,000 Shares for $1 Million. Is the Medical Tech Stock Now a Buy?
2026-09-30 16:28
•Brendan Coffey •The Motley Fool
••• • Axe Cap view
Insider Buying in Alphatec: A Signal Worth Watching?
Alphatec CEO's $1 million share purchase highlights confidence amid mixed performance.
Insider buying usually catches attention because it shows confidence from those who know the business best. Alphatec’s CEO just bought $1 million worth of shares, raising his stake further. The company posted solid Q2 sales growth of around 15% and saw more surgeons adopting its spinal surgery tech, which is encouraging. That said, the stock slumped 42% over the past year, suggesting the market isn’t convinced yet. For South African investors, Alphatec isn’t listed locally, so focus shifts to the rand’s movement against the dollar. The USD/ZAR pair is crucial here; a weaker rand means imported medical devices like those from Alphatec become pricier, impacting local hospital procurement. If the rand stays under pressure, international firms could face headwinds selling into South Africa. The positive momentum at Alphatec is real but tempered by currency risks and past volatility. this is just our opinion and not financial advice
Given Alphatec’s insider buying and growth signs, I’d watch the stock but not jump in. Locally, keep an eye on USD/ZAR to gauge imported medical tech exposure. Trim exposure if the rand weakens sharply.
- Alphatec Holdings (ATEC)
- USD/ZAR
- Continued share price decline despite insider buying
- Rand depreciation increasing local costs for medical imports
5/10
Alphatec Holdings CEO Miles Patrick purchased approximately 115,000 shares worth $1 million at a weighted average price of $8.81 per share on September 10, 2026. This insider buy increased his total beneficial ownership to 6.2 million shares worth $54.41 million. The article interprets this as a bullish signal, noting that insider purchases typically indicate confidence in future stock price appreciation. The company reported strong Q2 results with 15% sales growth and expanding surgeon adoption of its spinal surgery solutions.
Our take is based on reporting first published by The Motley Fool.